Vishnu Priyan

During the CheckMate-67T trial, the average administration time for BMS’ Opdivo Qvantig was approximately five minutes. Credit: Dennis Diatel/Shutterstock. The US Food and Drug Administration (FDA) has granted approval for Bristol Myers Squibb’s (BMS) Opdivo Qvantig for subcutaneous use to […]

Under the agreement, Mankind Pharma will have the exclusive rights to register, import, market, sell, and distribute Sintilimab in India. Credit: Piotr Swat/Shutterstock. Mankind Pharma has entered into a partnership with Innovent Biologics for exclusively licensing and commercialising Sintilimab, an

Datopotamab deruxtecan is intended for use in adults with locally advanced or metastatic nonsquamous NSCLC. Credit: New Africa/Shutterstock. AstraZeneca and Daiichi Sankyo have withdrawn their marketing authorisation application in the European Union (EU) voluntarily, intended for datopotamab deruxtecan (Dato-DXd), to

The company will focus on creating small molecule therapeutics that enhance the natural function of proteasomes. Credit: Gorodenkoff/Shutterstock. Booster Therapeutics has announced its inception, backed by a $15m investment, to develop a new class of proteasome activator medicines aimed at

Lilly will gain worldwide rights for the development and commercialisation of DACRA molecules to treat obesity. Credit: New Africa/Shutterstock. Nordic Bioscience subsidiary KeyBioscience has announced an extension of its strategic partnership with Eli Lilly, focusing on the development of a

Merck’s new €290m biosafety testing facility in Rockville features advanced testing capabilities. Credit: Merck/Business Wire. Germany-based Merck KGaA has announced the launch of a new €290m ($317.6m) biosafety testing facility in Rockville, Maryland, US. The 23,000m² Rockville facility will provide

The company’s single-cell-based discovery engine can detect the specific pathogenic cells that cause disease, and their surface markers. Credit: PeopleImages.com – Yuri A/Shutterstock. Arda Therapeutics has secured $43m in Series A financing to develop targeted cell depletion therapies. Andreessen Horowitz

Boehringer Ingelheim focuses on targeting the proteins involved in this process as a promising strategy for developing new cancer treatments. Credit: Tada Images/Shutterstock. Boehringer Ingelheim and Circle Pharma have entered a new research partnership and licence agreement to develop a

The company had sought approval for dasiglucagon for the treatment and prevention of hypoglycaemia in infants with congenital hyperinsulinism. Credit: Gorodenkoff/Shutterstock. The US Food and Drug Administration (FDA) has issued a complete response letter (CRL) to Zealand Pharma, declining the

City Therapeutics is developing an siRNA-engineering platform to design, enhance, and optimise RNAi-based medicines. Credit: PeopleImages.com – Yuri A/Shutterstock. City Therapeutics has announced its launch, accompanied by a $135m Series A financing to lead advancements in RNA interference (RNAi)-based medicine